Repaglinide (Mylan Pharmaceuticals Inc.)
Welcome to the PulseAid listing for the Repaglinide drug offered from Mylan Pharmaceuticals Inc.. This Glinide [EPC],Potassium Channel Antagonists [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | Mylan Pharmaceuticals Inc. |
NON-PROPRIETARY NAME: | repaglinide |
SUBSTANCE NAME: | REPAGLINIDE |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Glinide [EPC],Potassium Channel Antagonists [MoA] |
ROUTE: | ORAL |
DOSAGE FORM: | TABLET |
MARKETING CATEGORY NAME: | ANDA |
START MARKETING DATE: | 2013-08-27 |
END MARKETING DATE: | 0000-00-00 |
Repaglinide HUMAN PRESCRIPTION DRUG Details:
Item Description | Repaglinide from Mylan Pharmaceuticals Inc. |
LABELER NAME: | Mylan Pharmaceuticals Inc. |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 0.5(mg/1) |
START MARKETING DATE: | 2013-08-27 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 0378-3121_5d82267a-40dc-459f-877d-1d840097247e |
PRODUCT NDC: | 0378-3121 |
APPLICATION NUMBER: | ANDA090252 |
Other REPAGLINIDE Pharmaceutical Manufacturers / Labelers: